PDF(Pubmed)
Abstract：
UNASSIGNED: To compare the efficacy of EUS-guided celiac plexus neurolysis (CPN) and celiac plexus irradiation with iodine-125 (125I) seeds with absolute ethanol for relieving pain in patients with advanced pancreatic cancer.
UNASSIGNED: We retrospectively analyzed data of 81 patients with advanced pancreatic cancer who underwent EUS-CPN or EUS-125I implantation between January 2017 and December 2020. Postoperative pain was assessed using visual analog scale (VAS) scores; self-assessments of quality of life and the median survival time were compared between the 2 groups.
UNASSIGNED: EUS-CPN and 125I implantation were performed in 43 and 38 patients, respectively. Postoperative VAS scores were significantly lower than the preoperative levels in both groups. One week after the operation, 26 patients (60.5%) in the EUS-CPN group achieved partial pain relief, whereas no patients in the EUS-125I seed group experienced pain relief. However, after 4 weeks postoperatively, VAS scores had decreased, and the rate of partial pain relief was higher for EUS-125I seeds than for EUS-CPN. Self-assessments of quality of life were similar in both groups during the first 1 month after the procedure.
UNASSIGNED: Both EUS-CPN and EUS-125I seeds can safely and effectively relieve pain in patients with advanced pancreatic cancer. Although EUS-125I seeds take additional time to show effects, the extent and duration of pain relief are better compared with CPN, and interestingly, the median survival time was different.
UNASSIGNED: We retrospectively analyzed data of 81 patients with advanced pancreatic cancer who underwent EUS-CPN or EUS-125I implantation between January 2017 and December 2020. Postoperative pain was assessed using visual analog scale (VAS) scores; self-assessments of quality of life and the median survival time were compared between the 2 groups.
UNASSIGNED: EUS-CPN and 125I implantation were performed in 43 and 38 patients, respectively. Postoperative VAS scores were significantly lower than the preoperative levels in both groups. One week after the operation, 26 patients (60.5%) in the EUS-CPN group achieved partial pain relief, whereas no patients in the EUS-125I seed group experienced pain relief. However, after 4 weeks postoperatively, VAS scores had decreased, and the rate of partial pain relief was higher for EUS-125I seeds than for EUS-CPN. Self-assessments of quality of life were similar in both groups during the first 1 month after the procedure.
UNASSIGNED: Both EUS-CPN and EUS-125I seeds can safely and effectively relieve pain in patients with advanced pancreatic cancer. Although EUS-125I seeds take additional time to show effects, the extent and duration of pain relief are better compared with CPN, and interestingly, the median survival time was different.
摘要：
■比较EUS引导的腹腔神经丛神经松解术（CPN）和腹腔神经丛照射与碘125（125I）种子和无水乙醇缓解晚期胰腺癌患者疼痛的疗效。
我们回顾性分析了在2017年1月至2020年12月期间接受EUS-CPN或EUS-125I植入的81例晚期胰腺癌患者的数据。术后疼痛采用视觉模拟量表(VAS)评分进行评定,比较两组患者生活质量自评和中位生存时间。
■在43和38例患者中进行了EUS-CPN和125I植入，分别。两组术后VAS评分均显著低于术前水平。手术一周后，EUS-CPN组的26例患者（60.5%）实现了部分疼痛缓解，而EUS-125I种子组中没有患者疼痛缓解。然而,术后4周，VAS评分有所下降，EUS-125I种子的部分疼痛缓解率高于EUS-CPN。手术后的前1个月，两组的生活质量自我评估相似。
■EUS-CPN和EUS-125I种子均可安全有效地缓解晚期胰腺癌患者的疼痛。虽然EUS-125I种子需要额外的时间来显示效果，与CPN相比，疼痛缓解的程度和持续时间更好，有趣的是，中位生存时间不同.
我们回顾性分析了在2017年1月至2020年12月期间接受EUS-CPN或EUS-125I植入的81例晚期胰腺癌患者的数据。术后疼痛采用视觉模拟量表(VAS)评分进行评定,比较两组患者生活质量自评和中位生存时间。
■在43和38例患者中进行了EUS-CPN和125I植入，分别。两组术后VAS评分均显著低于术前水平。手术一周后，EUS-CPN组的26例患者（60.5%）实现了部分疼痛缓解，而EUS-125I种子组中没有患者疼痛缓解。然而,术后4周，VAS评分有所下降，EUS-125I种子的部分疼痛缓解率高于EUS-CPN。手术后的前1个月，两组的生活质量自我评估相似。
■EUS-CPN和EUS-125I种子均可安全有效地缓解晚期胰腺癌患者的疼痛。虽然EUS-125I种子需要额外的时间来显示效果，与CPN相比，疼痛缓解的程度和持续时间更好，有趣的是，中位生存时间不同.
